Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran.
- Javanbakht, Mehdi
- Moradi-Lakeh, Maziar
- Yaghoubi, Mohsen
- Esteghamati, Abdoulreza
- Mansour Ghanaie, Roxana
- Mahmoudi, Sussan
- Shamshiri, Ahmad-Reza
- Zahraei, Seyed Mohsen
- Baxter, Louise
- Shakerian, Sareh
- Chaudhri, Irtaza
- Fleming, Jessica A
- Munier, Aline
- Baradaran, Hamid R
DOIAbstract
BACKGROUND: Although the mortality from diarrheal diseases has been decreasing dramatically in Iran, it still represents an important proportion of disease burden in children <5 years old. Rotavirus vaccines are among the most effective strategies against diarrheal diseases in specific epidemiological conditions. This study aimed to evaluate the cost-effectiveness of the introduction of rotavirus vaccine (3 doses of pentavalent RotaTeq (RV5)) in Iran, from the viewpoints of Iran's health system and society. METHODS: The TRIVAC decision support model was used to calculate total incremental costs, life years (LYs) gained, and disability-adjusted life years (DALYs) averted due to the vaccination program. Necessary input data were collected fro...
Add to ORKG